Curative effect of tolvaptan in elderly patients with systolic heart failure

NIE Mao-xiao; ZHAO Quan-ming; TIAN Chang-rong

doi:10.3969/j.issn.1674-4055.2016.06.19

Abstract：Objective To observe the curative effect of tolvaptan in elderly patients with systolic heart failure (SHF).Methods The patients with SHF from grade II to IV (n=58, male 33, female 25, aged from 64 to 83 and average age=68.3±3.7) were chosen continuously from Jan. 2013 to Jan. 2014, and then randomly divided into control group (n=28) and tolvaptan group (n=30). Besides of relevant treatment, control group was given intravenous injection of furosemide once a day, and tolvaptan group was orally given tolvaptan once a day for 5 d. The changes of laboratory indexes [including urine volume, blood sodium, blood potassium and serum creatinine (SCr)] and cardiac echocardiogram indexes [ratio of early-diastolic fast filling velocity and late-diastolic fast filling velocity (E/A), left ventricular end-diastolic inner diameter (LVEDd) and left ventricular ejection fraction (LVEF)], and grade of New York Heart Function Assessment (NYHA) were respectively detected in 2 groups.Results After treatment for 5 d, urine volume and blood sodium level increased significantly in tolvaptan group compared with control group (allP<0.05). In tolvaptan group, E/A was (1.38±0.11) and LVEF was (57.1±2.9)%, which were significantly higher than those in control group [1.20±0.09, (49.8±4.7)%], and LVEDd was lower in tolvaptan group than that in control group [(48.1 ±4.5) mm vs. (54.1±4.5) mm, allP<0.05]. The percentage of patients with NYHA grade II was significantly higher in tolvaptan group than that in control group (80.0%vs. 42.9%) after treatment (P<0.05).Conclusion Tolvaptan can relieve the symptoms of SHF in elderly patients with higher clinical application value.